Abstract: Compositions and methods for the formulation and use of recombinant adeno-associated viruses (rAAVs) are described. In certain embodiments, the application discloses recombinant Adeno-Associated Virus (rAAV or AAV) formulations that provide for one or more of the following: maintain stable freeze-thaw and lyophilization (freeze-drying) performance, and enable longer term shelf storage at temperatures above-80° C. while maintaining critical quality attributes such as genome recovery, retention of potency, minimal aggregation and degradation, improved vector quality, retaining viral protein (VP) ratios, maximum chemical stability (minimal deamidation and oxidation) and/or improved thermodynamic stability.